PRKN and neoplasm: PARK2 mutations are known to cause Parkinson's disease and have also been identified in human malignancies, including lung cancer, and are associated with the potential to inhibit cancer cell growth in vitro [21], suggesting that PARK2 may function as a tumor suppressor gene.